Labopharm Reports Results for Third Quarter F...(ent of obligations under capital...),Health

Date:11/6/2009

ent of obligations under capital leases (68) (66) (199) (138) Proceeds from issuance of long-term debt 2,549 - 2,549 - Transaction costs (8) - (362) (118) Proceeds from issuance of share capital 366 3 527 8 Issuance costs of share capital (35) - (35) - ------------------------------------------------------------------------- 2,804 (63) 2,480 (248) ------------------------------------------------------------------------- Foreign exchange (loss) gain on cash held in foreign currencies (581) (176) (1,258) 448 Net increase (decrease) in cash and cash equivalents during the period 269 (16,829) 6,155 (1,445) Cash and cash equivalents, beginning of period 14,259 32,557 8,373 17,173 ------------------------------------------------------------------------- Cash and cash equivalents, end of period 14,528 15,728 14,528 15,728 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Supplemental cash flow information: Interest paid 802 632 2,294 1,777 Income taxes received 128 224 216 267 ------------------------------------------------------------------------- -------------------------------------------------------------------------

SOURCE Labopharm Inc.

'/>"/>

SOURCE Labopharm Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
2. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
3. Labopharm submits response to FDA for novel antidepressant
4. Labopharm Reports Results for Second Quarter Fiscal 2009
5. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
6. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Labopharm amends debt facility agreement with Hercules
9. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
10. Labopharm Reports Results for First Quarter Fiscal 2009
11. Labopharm announces details for first quarter results conference call and annual meeting